SynthesisJournal of neurology2026
Blood-based biomarkers for predicting prognosis in patients with subarachnoid hemorrhage: a systematic review and network meta-analysis.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis network meta-analysis aimed to evaluate the predictive value of different blood biomarkers for the prognosis of patients with subarachnoid hemorrhage.
methodsPubMed, Embase, Cochrane Library, and Web of Science databases were searched to collect relevant studies published in the last decade. Included studies reported sensitivity or specificity. The quality of included studies was assessed using the QUADAS-2 tool, and network meta-analysis was performed using STATA 18.0. The area under the cumulative ranking curve was calculated to compare the diagnostic efficacy of different biomarkers.
resultsA total of 38 studies involving 53 blood biomarkers were included. Among inflammatory markers, cleaved receptors for advanced glycation end-products (cRAGE) (SUCRA: sensitivity 75.9%, specificity 45.4%) showed relatively high predictive efficacy. Among immune cell counts, the fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) (SUCRA: sensitivity 69.4%, specificity 37.1%) performed particularly well. Among electrolytes and metabolites, maximum sodium concentration (Na
conclusioncRAGE, F-NLR, and Na⁺max show relatively high sensitivity or specificity and may be considered as the preferred indicators in future clinical research and practice.
Indexed as
Identifiers
42632835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.